JMP Securities analyst Jonathan Wolleben raised the firm’s price target on ProQR Therapeutics (PRQR) to $8 from $5 and keeps an Outperform rating on the shares as part of a broader note on Biotechnology. The firm highlighted key upcoming catalysts for its coverage universe over the next 12 months, ahead of what is shaping up to be a “busy” 2025, and noted that it still has several events expected between now and the end of the year which could provide a reason for “cheer” this holiday season.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Therapeutics Highlights Q3 2024 Financial Results
- ProQR Therapeutics price target raised to $10 from $5 at H.C. Wainwright
- ProQR Therapeutics price target raised to $4 from $2.50 at Chardan
- ProQR Therapeutics Shows Revenue Growth Amid Financial Challenges
- ProQR Therapeutics reports Q3 EPS (EUR 0.10) vs. (EUR 0.07) last year